(NP (-LRB- -LCB-) (NP (NN Effect)) (PP (IN of) (NP (NP (JJ antihypertensive) (NN therapy)) (PP (IN with) (NP (NN captopril))))) (PP (IN on) (NP (NP (NP-COOD (NP (NP (JJ gluco-)) (NP (-NONE- *?*))) (CC and) (NP (NN mineralocorticoid))) (NNS receptors)) (PP (IN of) (NP (NP (JJ peripheral) (NN blood) (NNS lymphocytes)) (PP (IN in) (NP (NP (JJ hypertensive) (NNS patients)) (PP (IN of) (NP (JJ various) (NN age))))))))) (-RRB- -RCB-))
(S (NP-SBJ-52 (NP (NN Binding)) (PP (IN of) (NP-COOD (NP (NN 3H-dexamethasone)) (CC and) (NP (NN 3H-aldosterone)))) (PP (IN by) (NP (JJ peripheral) (NN lymphocyte) (NNS receptors)))) (VP (VBD was) (VP (VBN investigated) (NP (-NONE- *-52)) (PP (IN in) (NP-COOD (NP (JJ healthy) (NNS persons)) (CC and) (NP (JJ hypertensive) (NNS patients)))) (PP-TMP (PP-COOD (PP (IN before) (NP (-NONE- *RNR*-53))) (CC and) (PP (IN after) (NP (-NONE- *RNR*-53)))) (NP-53 (ADJP (JJ 2-week)) (NN captopril) (NN treatment))))) (. .))
(S (NP-SBJ-54 (NP (DT The) (NN number)) (PP (IN of) (NP (NP-COOD (NP (NN glucocorticoid)) (CC and) (NP (NN mineralocorticoid))) (NN binding) (NNS sites)))) (VP (VBD was) (VP (VBN increased) (NP (-NONE- *-54)) (PP (IN in) (NP-COOD (NP (NNS hypertensives)) (CC vs) (NP (NNS normotensives)))))) (. .))
(S (NP-SBJ (NP (DT The) (NN treatment)) (PP (IN with) (NP (DT the) (NN ACE) (NN inhibitor) (NN captopril)))) (VP (VBD led) (PP (TO to) (NP (NP (NN activation)) (PP (IN of) (NP (NN hormone-receptor) (NNS interactions)))))) (. .))
(S (NP-SBJ (EX There)) (VP (VBD was) (NP-PRD (NP (DT a) (ADJP (RBR more) (JJ marked)) (NN rise)) (PP (IN of) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NNS receptors))))) (PP (IN in) (NP-COOD (NP (ADJP (ADJP (JJ middle-aged)) (PRN (-LRB- -LRB-) (NP (QP (CD 44-55)) (NNS years)) (-RRB- -RRB-))) (NNS hypertensives)) (CC vs) (NP (ADJP (ADJP (JJ elderly)) (PRN (-LRB- -LRB-) (NP (QP (CD 61-80)) (NNS years)) (-RRB- -RRB-))) (NNS subjects))))) (PP-TMP (IN after) (NP (NN captopril) (NN treatment)))) (. .))
